Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kavanaugh Hearings: Dems Tell Judge Abortion Rights, Preexisting Conditions Top Their Concerns

Executive Summary

Democrats on the Senate Judiciary Committee told Supreme Court nominee Brett Kavanaugh on the first day of confirmation hearings Tuesday they will question his rulings on abortion and women’s reproductive rights, and on retaining federal insurance coverage for people with preexisting conditions under Obamacare. As the potential conservative swing vote on the high court, Kavanaugh’s decisions can impact sales of contraceptive devices and medtech to treat heart disease, cancer, diabetes and an array of other preexisting conditions.

You may also be interested in...



Kavanaugh’s Potential Rulings On ACA’s 10 Essential Benefits Could Impact Medtech Coverage

An analysis of Supreme Court nominee Brett Kavanaugh’s prior rulings opposing the Affordable Care Act, and how his weight on ACA cases coming before the high court may remove some marketplace insurance for medtech products for preexisting illnesses and mental health that are currently covered.

How Kavanaugh High Court Pick Could Increase IUD Sales

A look at what impacts a changed court could have on abortion rights, and related IUD products that device companies Bayer and Allergan make and sell, plus a peek at new contraceptive products on the horizon.

Leap In US Sales Of IUDs Linked To Trump Election, ACA Repeal Efforts

Sales of contraceptive intrauterine devices rose in the 4th quarter of 2016 at some companies. The increase in interest in IUDs coincides with efforts to repeal Obamacare and eliminate contraceptive coverage guarantees, according to Planned Parenthood and AthenaHealth.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT123241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel